COVID-19 prompts Pfizer to stop enrollment in most studies

Pfizer has paused enrollment in many new and ongoing clinical trials in response to the COVID-19 pandemic, Reuters reports. The action sees Pfizer join Bristol Myers Squibb and Eli Lilly on the list of Big Pharma companies to revise their R&D plans in light of the novel SARS-CoV-2 coronavirus.

Each company has responded slightly differently to the situation. In Pfizer’s case, the current plan is to hold off on enrolling patients in many new and ongoing global trials for three weeks. The only exceptions are studies that are enrolling people with life-threatening conditions who are running out of treatment options.

CLICK HERE FOR MORE